Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Annals of Oncology - Tập 28 Số 2 - Trang 270-277 - 2017
Luis Paz‐Ares1, Eng-Huat Tan2, Kenneth V. Honn3, L. Zhang4, Vera Hirsh5, Michael Boyer6, James Chih‐Hsin Yang7, Tony Mok8, K.H. Lee9, Shun Lü10, Yajun Shi11, D. H. Lee12, Janessa Laskin13, D.-W. Kim14, Scott A. Laurie15, Karl Kölbeck16, Jean Fan17, Nigel Dodd18, Tim F. Greten19, K. Park20
1Medical Oncology Department, Hospital Universitario Doce de Octubre, Universidad Complutense and CNIO, Madrid, Spain
2Division of Medical Oncology, National Cancer Centre, Singapore
3Cancer Section, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia
4State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
5Department of Oncology, McGill University, Montreal, Canada
6Department of Medical Oncology, Chris O’Brien Lifehouse, Camperdown, Australia
7Department of Oncology, National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan
8Department of Clinical Oncology, State Key Laboratory of South China, The Chinese University of Hong Kong, Hong Kong
9Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea
10Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai
11Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
12Department of Oncology, Asan Medical Center, Seoul, South Korea
13Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
14Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
15Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
16Pulmonary Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden
17Clinical Program Leader, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
18Biostatistics, Boehringer Ingelheim Ltd UK, Bracknell, UK
19TA Oncology, Boehringer Ingelheim GmbH, Ingelheim, Germany
20Division of Hematology–Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Tóm tắt

Từ khóa


Tài liệu tham khảo

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806

Wu, 2014, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 213, 10.1016/S1470-2045(13)70604-1

Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann Oncol, 26, 1883, 10.1093/annonc/mdv270

Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X

Park, 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, 17, 577, 10.1016/S1470-2045(16)30033-X

Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 16, 141, 10.1016/S1470-2045(14)71173-8

Zhou, 2015, Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802), Ann Oncol, 26, 1877, 10.1093/annonc/mdv276

Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235

Inoue, 2013, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002), Ann Oncol, 24, 54, 10.1093/annonc/mds214

Yoshioka, 2014, J Clin Oncol, 32 (Suppl. 15)

Lee, 2015, Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, J Clin Oncol, 33, 1958, 10.1200/JCO.2014.58.1736

Inoue, 2011, Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations, J Clin Oncol, 29 (Suppl. 15)

Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet Oncol, 13, 528, 10.1016/S1470-2045(12)70087-6

Schuler, 2016, Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial, Ann Oncol, 27, 417, 10.1093/annonc/mdv597

Cappuzzo, 2016, Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer, Lung Cancer, 99, 31, 10.1016/j.lungcan.2016.06.008

Pilz, 2012, Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?, Transl Lung Cancer Res, 1, 26

Janne, 2015, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, 372, 1689, 10.1056/NEJMoa1411817

Park, 2015, Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI), J Clin Oncol, 33 (Suppl. 15)

Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073

Wu, 2016, The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients, Oncotarget, 7, 12404, 10.18632/oncotarget.7189

Yang, 2015, A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901), J Thorac Oncol, 10, S321

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 28 Số 2

270-277

Thông tin tác giả